Teva Raises 2026 Revenue Outlook as Q3 Non-GAAP EPS Rises 10.3% to $0.86
Teva Pharmaceutical raised its 2026 revenue forecast to $16.7 billion to $17.0 billion after third-quarter non-GAAP EPS rose 10.3% to $0.86, as fast-growing branded drugs such as AUSTEDO and AJOVY offset a steep drop in U.S. generics.
Revenue slipped 1.9% to $4.40 billion from $4.48 billion a year earlier, according to the earnings release Teva filed with an 8-K on Tuesday. The company said the decline was driven by generic competition to lenalidomide, the cancer drug sold as Revlimid. GAAP net income fell to $233 million, or $0.20 per diluted share, from $433 million, or $0.37, with financial expenses including a $224 million loss on debt extinguishment.
Non-GAAP net income rose to $1.01 billion from $910 million. Non-GAAP gross margin widened to 58.7% from 55.3%, and non-GAAP operating income grew to $1.39 billion, a 31.7% margin, from $1.29 billion. Adjusted EBITDA rose 7.3% to $1.50 billion.
Branded drugs carry the quarter
AUSTEDO revenue grew 21% in local currency to $751 million, and Teva lifted its 2026 outlook for the movement-disorder drug to $2.55 billion to $2.65 billion from $2.45 billion to $2.60 billion. AJOVY sales jumped 61% to $269 million, with its outlook raised to $930 million to $960 million from $850 million to $870 million. UZEDY revenue rose 96% to $85 million, and its forecast increased to $290 million to $310 million from $270 million to $290 million.
U.S. segment revenue fell 11% to $1.87 billion as U.S. generics revenue dropped 39% to $718 million. Europe grew 7% to $1.32 billion and International Markets rose 6% to $592 million. Teva said biosimilar revenue is expected to exceed $0.8 billion in 2026, reaching its 2027 goal a year early.
Guidance moves
Teva's updated 2026 outlook:
- Revenue: $16.7 billion to $17.0 billion, up from $16.5 billion to $16.85 billion
- Non-GAAP operating income: $3.8 billion to $3.9 billion, from $3.8 billion to $4.0 billion, including $0.87 billion of IPR&D charges
- Adjusted EBITDA: $4.23 billion to $4.43 billion, from $4.23 billion to $4.53 billion
- Non-GAAP EPS: $1.92 to $2.11, from $1.91 to $2.11, including $0.71 of IPR&D
- Free cash flow: $2.1 billion to $2.4 billion, from $2.0 billion to $2.4 billion
Pipeline and balance sheet
The FDA approved WELTRUZA in October, and Teva set a peak sales target of $1.5 billion to $2.0 billion for its long-acting schizophrenia portfolio. The company acquired BXCL-501 from BioXcel, signed a biosimilars deal with Samsung Bioepis covering infliximab and etanercept, and said the FDA accepted its ecopipam application with an action date in the first quarter of 2027. It discontinued a study of emrusolmin in multiple system atrophy.
Moody's and S&P both upgraded Teva to investment grade. The company redeemed $4.68 billion of notes and issued $4.84 billion of new debt in a refinancing, and it finalized a most-favored-nation pricing agreement with the U.S. Administration. Total debt stood at $16.72 billion at quarter-end.
By the numbers
- Revenue: $4.40 billion, down 1.9%
- Non-GAAP EPS: $0.86, up 10.3%
- GAAP diluted EPS: $0.20, versus $0.37
- AUSTEDO revenue: $751 million, up 21% in local currency
- Adjusted EBITDA: $1.50 billion, up 7.3%
- 2026 revenue outlook: $16.7 billion to $17.0 billion, raised
Sources
- Teva Pharmaceutical Form 8-K with third-quarter 2026 earnings release, filed Nov. 3, 2026 (accession 0001171843-26-007054)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.